Omeros Corporation

OMERApproved

Omeros Corporation is a publicly traded biopharmaceutical company that leverages its expertise in immunology and inflammation to develop novel therapeutics. The company has built a portfolio around its commercial ophthalmology product, OMIDRIA, and is advancing multiple clinical-stage candidates, most notably its MASP-2 inhibitor narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Omeros's strategy involves targeting both niche, high-need orphan diseases and larger commercial markets through its proprietary research platforms.

Market Cap

$287.1M

Employees

200-300

Focus

Biotech

OMER · Stock Price

USD 4.054.68 (-53.61%)

Historical price data

AI Company Overview

Technology Platform

Focuses on the lectin pathway of the complement system, with a first-in-class MASP-2 inhibitor, and has a legacy platform for de-orphanizing G protein-coupled receptors (GPCRs).

Pipeline Snapshot

29 drugs in pipeline, 11 in Phase 3

Drug	Indication	Stage
1% preservative-free lidocaine + Phenylephrine 1.0%/ Ketorolac 0.3%	Pain Reduction	Approved
Omidria	Cataract	Approved
OMS103HP + Vehicle	Anterior Cruciate Ligament Reconstruction	Phase 3
OMS302 + Placebo	Intraocular Lens Replacement	Phase 3
OMS103HP + Vehicle	Knee Injuries	Phase 3

FDA Approved Drugs

YARTEMLEABLADec 23, 2025

Opportunities

Major near-term opportunity lies in the potential FDA approval and launch of narsoplimab for HSCT-TMA, a first-in-class therapy for a deadly condition.

Further opportunities exist in expanding narsoplimab's label to IgA Nephropathy and aHUS, and in advancing the novel MASP-3 inhibitor OMS906 in the large PNH market and other complement disorders.

Risk Factors

Key risks include regulatory rejection or delay for narsoplimab, failure in ongoing Phase 3 trials, intense competition in the complement space from larger players, continued financial losses requiring dilutive financing, and commercial execution challenges for launched products.

Competitive Landscape

Faces competition from generics in ophthalmology and from established (Alexion/AstraZeneca) and emerging complement inhibitors (Apellis, Novartis) in immunology. Omeros's differentiation is based on its selective lectin-pathway inhibition with narsoplimab and its novel MASP-3 target with OMS906, aiming for efficacy in specific patient populations where broader complement inhibition may be suboptimal or carry greater risk.

Publications

Patents

Pipeline

FDA Approvals